CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabineRaphaëlle Fanciullino, Régis Costello, Vadim Ivanov et al.|Blood Advances|2018Cited by 43
Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patientsMélanie Donnette, Raphaëlle Fanciullino, Caroline Solas et al.|Journal of Chromatography B|2019Cited by 12
Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351Mélanie Donnette, Raphaëlle Fanciullino, Mourad Hamimed et al.|Journal of Controlled Release|2021Cited by 9
Pharmacokinetics/pharmacodynamics of liposomal cytarabine (VYXEOS) in AML patients: Influence of cytidine deaminase genetic polymorphisms.Mélanie Donnette, Raphaëlle Fanciullino, Geoffroy Venton et al.|Journal of Clinical Oncology|2020Cited by 3
Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in LAM patientsMélanie Donnette, Raphaëlle Fanciullino, Caroline Solas et al.|Journal of Chromatography A|2019Cited by 0